Do Analysts Recommend THC at $53.26?

Tenet Healthcare surged to $53.26 per share this None, but it remains 26530.0% above its mean target price of $0.2. There may still be room for more downwards movement — even after today's 3.0% drop. Analysts are giving the mid-cap Medical Care Facility stock on average rating of buy, with target prices ranging from $0.2 to $0.2 per share.

Tenet Healthcare has an average level of shares sold short, at 5.3% of its total share float. The stock's short ratio (also called days to cover) is 3.61. Since 1.43% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Institutional investors own 102.1% of Tenet Healthcare's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Tenet Healthcare

Holder Shares Date Reported Percentage Value
Vanguard Group, Inc. (The) 10,846,645 2022-09-29 10% $577,692,294
Blackrock Inc. 9,632,644 2022-09-29 9% $513,034,603
Glenview Capital Management, Llc 8,099,648 2022-09-29 7% $431,387,238
Invesco Ltd. 6,686,104 2022-09-29 6% $356,101,887
FMR, LLC 6,459,026 2022-09-29 6% $344,007,713
Harris Associates L.P. 5,543,569 2022-09-29 5% $295,250,475
Camber Capital Management LP 3,000,000 2022-09-29 3% $159,779,994
State Street Corporation 2,928,171 2022-09-29 3% $155,954,382
Samlyn Capital, LLC 2,811,314 2022-09-29 3% $149,730,578
Assenagon Asset Management S.A. 1,955,734 2022-12-30 2% $104,162,389
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.